According to the phase IIb study of apatinib in TNBC, hand-foot syndrome (17.0%), proteinuria (13.6%), hypertension (11.9%), increased alanine aminotransferase (11.9%), and fatigue (3.4%) were the most frequent grade 3/4 non-hematologic effects14. Here, GPT is linked to Hand-foot syndrome.